Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last CNY64.66 CNY
Change Today -0.28 / -0.43%
Volume 2.9M
As of 3:00 AM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

china national accord medi-a (000028) Snapshot

Open
CNY63.00
Previous Close
CNY64.94
Day High
CNY64.82
Day Low
CNY62.15
52 Week High
06/8/15 - CNY94.11
52 Week Low
12/1/14 - CNY44.18
Market Cap
21.5B
Average Volume 10 Days
3.4M
EPS TTM
CNY1.90
Shares Outstanding
307.7M
EX-Date
05/22/15
P/E TM
34.0x
Dividend
CNY0.20
Dividend Yield
0.31%
Current Stock Chart for CHINA NATIONAL ACCORD MEDI-A (000028)

Related News

No related news articles were found.

china national accord medi-a (000028) Related Businessweek News

No Related Businessweek News Found

china national accord medi-a (000028) Details

China National Accord Medicines Co., Ltd. engages in the distribution of medicine and pharmaceutical products. It also manufactures medicines. The company is based in Shenzhen, China. China National Accord Medicines Co., Ltd. is a subsidiary of Sinopharm Holding Co., Ltd.

4,431 Employees
Last Reported Date: 03/20/15

china national accord medi-a (000028) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

china national accord medi-a (000028) Key Developments

China National Accord Medicines Corporation Ltd. Reports Unaudited Earnings Results for the Six Months Ended June 30, 2015

China National Accord Medicines Corporation Ltd. reported unaudited earnings results for the six months ended June 30, 2015. For the period, the company reported operating income of RMB 12,813,803,166.77 compared to RMB 11,612,642,434.28 a year ago. Net profit attributable to shareholders of the listed company was RMB 387,319,252.33 compared to RMB 349,213,988.51 a year ago. Net cash flow arising from operating activities was RMB 448,239,578.73 compared to net cash outflow from operating activities of RMB 484,715,807.96 a year ago. Basic and diluted earnings per share were RMB 1.068 compared to RMB 1.073 a year ago. Weighted average ROE was 7.85% compared to 10.39% a year ago.

China National Accord Medicines Corporation Ltd. to Report First Half, 2015 Results on Aug 20, 2015

China National Accord Medicines Corporation Ltd. announced that they will report first half, 2015 results on Aug 20, 2015

China National Accord Medicines Corporation Ltd.(SZSE:000028) added to Shenzhen Stock Exchange Component A Share Index

China National Accord Medicines Corporation Ltd. has been added to Shenzhen Stock Exchange Component A Share Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
000028:CH CNY64.66 CNY -0.28

000028 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
China BCT Pharmacy Group Inc $0.0062 USD 0.00
View Industry Companies
 

Industry Analysis

000028

Industry Average

Valuation 000028 Industry Range
Price/Earnings 33.1x
Price/Sales 0.9x
Price/Book 4.5x
Price/Cash Flow 28.1x
TEV/Sales 0.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHINA NATIONAL ACCORD MEDI-A, please visit www.szaccord.com.cn. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.